Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

2015 ◽  
Vol 55 (2) ◽  
pp. 209-223 ◽  
Author(s):  
Eef Hoeben ◽  
Willem De Winter ◽  
Martine Neyens ◽  
Damayanthi Devineni ◽  
An Vermeulen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Healthy Volunteers ◽  
Pharmacokinetic Modeling ◽  
Population Pharmacokinetic ◽  
Population Pharmacokinetic Modeling

scholarly journals Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Jia Liu ◽  
Ziqiang Li ◽  
Hua Liu ◽  
Xianhua Wang ◽  
Chunxiao Lv ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Healthy Volunteers ◽  
Clinical Indication ◽  
Chinese Patent Medicine ◽  
Significant Difference ◽  
Chinese Patent ◽  
Patent Medicine

Tangzhiqing tablet (TZQ) is derived from Tangzhiqing formula, which has been used to regulate glucose and lipid metabolism in China for hundreds of years. However, as a new Chinese patent medicine, its clinical indication is not clear. To explore the clinical indication and effect on the patients with type 2 diabetes mellitus (T2DM), a pilot clinical trial and metabolomics study were carried out. In the clinical study, T2DM patients were divided into three groups and treated with TZQ, placebo, or acarbose for 12 weeks, respectively. The metabolomic study based on UPLC Q-TOF MS was performed including patients with hypertriglyceridemia in TZQ and placebo groups and healthy volunteers. The clinical results showed that TZQ could reduce glycosylated hemoglobin (HbA1c) and fasting insulin. For patients with hypertriglyceridemia in TZQ group, the levels of HbA1c all decreased and were correlated with the baseline level of triglyceride. Metabonomics data showed a significant difference between patients and healthy volunteers, and 17 biomarkers were identified. After 12-week treatment with TZQ, 11 biomarkers decreased significantly (p<0.05), suggesting that TZQ could improve the metabolomic abnormalities in these participants. In conclusion, the clinical indication of TZQ was T2DM with hypertriglyceridemia, and its target was related to glycerophospholipid metabolism.

scholarly journals Laser Doppler Spectrum Analysis Based on Calculation of Cumulative Sums Detects Changes in Skin Capillary Blood Flow in Type 2 Diabetes Mellitus

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 267
Author(s):  
Igor Kozlov ◽  
Evgeny Zherebtsov ◽  
Galina Masalygina ◽  
Konstantin Podmasteryev ◽  
Andrey Dunaev
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Healthy Volunteers ◽  
Laser Doppler ◽  
Doppler Spectrum ◽  
Diabetic Patients ◽  
Practical Result ◽  
Cumulative Sums

In this article, we introduce a new method of signal processing and data analysis for the digital laser Doppler flowmetry. Our approach is based on the calculation of cumulative sums over the registered Doppler power spectra. The introduced new parameter represents an integral estimation for the redistribution of moving red blood cells over the range of speed. The prototype of the device implementing the technique is developed and tested in preliminary clinical trials. The methodology was verified with the involvement of two age groups of healthy volunteers and in a group of patients with type 2 diabetes mellitus. The main practical result of the study is the development of a set of binary linear classifiers that allow the method to identify typical patterns of the microcirculation for the healthy volunteers and diabetic patients based on the presented diagnostic algorithm.

P1016EMPAGLIFLOZIN REDUCES URINARY MITOCHONDRIAL DNA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Haekyung Lee ◽  
Wonmi Yang ◽  
Hyoungnae Kim ◽  
Jin Seok Jeon ◽  
Hyunjin Noh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Mitochondrial Dna ◽  
Mitochondrial Dysfunction ◽  
Healthy Volunteers ◽  
Quantitative Polymerase Chain Reaction ◽  
Sglt2 Inhibitors ◽  
Copy Numbers

Abstract Background and Aims Recent evidences has shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular and renal outcomes of type 2 diabetes mellitus (T2DM) patients. However, the mechanisms by which SGLT2 inhibitors improve clinical outcomes are unclear. Mitochondrial dysfunction plays a principal role in the pathophysiology of T2DM and its complications. We hypothesized empagliflozin, an SGLT2 inhibitor improves mitochondrial dysfunction in T2DM patients. Method We prospectively recruited healthy volunteers (n = 22) and SGLT2 naïve T2DM patients (n = 21). Copy numbers of urinary and serum mitochondrial DNA (mtDNA) nicotinamide adenine dinucleotide dehydrogenase subunit-1 (mtND-1) and cytochrome-c oxidase 3 (mtCOX-3) were measured using quantitative polymerase chain reaction in healthy volunteers and T2DM patients at baseline and in T2DM patients after 3 months of treatment with empagliflozin (10 mg, n = 17 or 25 mg, n = 4). Results Patients with T2DM were older than healthy volunteers and had higher body mass index and systolic blood pressure, but lower estimated glomerular filtration rate. Urinary mtND-1 and mtCOX-3 copy numbers were significantly higher in the T2DM group than in healthy volunteers. Urinary mtDNA copy numbers were correlated with diabetes duration (8.74 ± 7.60 years, r = 0.54, P = 0.01 for mtND-1, r = 0.50, P = 0.02 for mtCOX-3). Urinary copy numbers of mtND-1 and mtCOX-3 decreased after empagliflozin treatment. The amount of reduction of urinary mtDNA copy number did not differ according to empagliflozin dose (P = 0.897 for mtND-1, P = 0.462 for mtCOX-3). Conclusion In this study, we found that T2DM is associated with elevated urinary mtND-1 and mtCOX-3 copy numbers. Empagliflozin reduces the elevated urinary mtND-1 and mtCOX-3 copy numbers in patients with T2DM. Our results suggest that empagliflozin could attenuate mitochondrial damage in the kidney cells of T2DM patients.

Aliskiren Exhibits Similar Pharmacokinetics in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

2006 ◽  
Vol 45 (11) ◽  
pp. 1125-1134 ◽  
Author(s):  
Charlie Zhao ◽  
Sujata Vaidyanathan ◽  
Ching-Ming Yeh ◽  
Mojdeh Maboudian ◽  
Hans Armin Dieterich
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Healthy Volunteers
Sign in / Sign up

Export Citation Format

Share Document